Table 4 Exploratory outcomes (presented as rates per patient-year)
Outcome | Patient sample | Period | Control PCPs | Intervention PCPs Waivered | |
|---|---|---|---|---|---|
n = 23 | No n = 24 | Yes n = 8 | |||
OUD diagnosis | Higher risk for OUD | Pre | 0.008 | 0.005 | 0.013 |
Post | 0.062 | 0.149 | 0.152 | ||
Post/pre | 7.87 | 28.54 | 11.30 | ||
Buprenorphine starts | Higher risk for OUD | Pre | 0 | 0 | 0 |
Post | 0 | 0.029 | 0.015 | ||
Post/pre | NA | NA | NA | ||
Buprenorphine starts | Diagnosed with OUD | Pre | 0.359 | 0.566 | 3.666 |
Post | 0.368 | 0.625 | 5.127 | ||
Post/pre | 1.03 | 1.10 | 1.40 | ||
Naltrexone starts | Higher risk for OUD | Pre | 0 | 0 | 0 |
Post | 0.030 | 0.019 | 0.041 | ||
Post/pre | NA | NA | NA | ||
Naltrexone starts | Diagnosed with OUD | Pre | 0.049 | 0.049 | 0.053 |
Post | 0.020 | 0.074 | 0.045 | ||
Post/pre | 0.42 | 1.52 | 0.85 | ||
Naloxone starts | Higher risk for OUD | Pre | 0.133 | 0.176 | 0.256 |
Post | 0.157 | 0.166 | 0.122 | ||
Post/pre | 1.18 | 0.95 | 0.48 | ||
Naloxone starts | Diagnosed with OUD | Pre | 0.310 | 0.486 | 0.481 |
Post | 0.286 | 0.294 | 0.295 | ||
Post/pre | 0.92 | 0.61 | 0.61 | ||
Referrals to specialty care | Higher risk for OUD | Pre | 0.106 | 0.101 | 0.103 |
Post | 0.149 | 0.130 | 0.162 | ||
Post/pre | 1.41 | 1.29 | 1.57 | ||
Referrals to specialty care | Diagnosed with OUD | Pre | 0.238 | 0.205 | 0.283 |
Post | 0.247 | 0.247 | 0.281 | ||
Post/pre | 1.04 | 1.21 | 0.99 | ||